Datroway nabs FDA approval for immunotherapy-ineligible triple-negative breast cancer

medpagetoday.com·May 26, 2026 · 2 mesi fa

New First-Line Option Approved in Triple-Negative Breast Cancer

morningstar.com·May 22, 2026 · 3 mesi fa

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates

pharmaceutical-technology.com·May 25, 2026 · 2 mesi fa

AstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBC

endpoints.news·May 22, 2026 · 3 mesi fa

FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval

fiercepharma.com·May 22, 2026 · 3 mesi fa

AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway

medpagetoday.com·May 18, 2026 · 3 mesi fa

Blockbuster Drug Gets Breast Cancer Approvals in Curative Setting